Transcatheter Edge-To-Edge Valve Repair for Tricuspid Regurgitation

Key Messages

• The transcatheter edge-to-edge valve repair (TEER) device (TriClip) might be more effective in reducing tricuspid regurgitation severity and improving quality of life compared to medical therapy alone.
• The TEER device (TriClip) may have little impact on all-cause mortality, hospitalization due to heart failure, and 6-minute walk tests compared to medical therapy alone.
• The TEER device (TriClip) demonstrated a numerically higher rate of adverse events than a medical therapy control group in a clinical trial.
• Patients treated with the TEER device (TriClip) had fewer major adverse events (ranging from 2.5% to 7.1%) than the 10% performance goal in the included clinical trial; common major adverse events included major bleeding, single leaflet device attachment, and nonelective cardiovascular surgery. No device embolization or thrombosis were reported.
• We did not identify any studies that met our inclusion criteria to evaluate the effectiveness of the TEER device (TriClip) compared to open heart surgery.